Results 51 to 60 of about 51,731 (234)

Efficacy of combined atorvastatin and argatroban therapy in acute cerebral infarction

Pakistan Journal of Pharmaceutical Sciences
Background: Acute cerebral infarction (ACI) is a disease which seriously affects the people's health. Objectives: To investigate the efficacy of combined atorvastatin and argatroban therapy in patients with ACI and its effects on cerebral hemodynamics ...
Weihua Xu, Ni Zhai, Yanan Wang, Jie Chen, Zhiwei Li, Licang Zhu   +5 more
doaj   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Clinical Pharmacology &Therapeutics, EarlyView.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee, Yoon‐A Park, Yubin Song, Ji‐Min Han, Kyung Hee Choi, Myeong Gyu Kim, Hye Sun Gwak   +6 more
wiley   +1 more source

Atorvastatin before percutaneous coronary intervention: A systematic review and meta-analysis.

PLoS ONE
Atorvastatin is widely recommended for long-term secondary prevention in STEMI patients with no contraindication. Although high-dose atorvastatin has been shown to reduce important patient outcomes such as MACE, there is still doubt that high-dose ...
Mariano García-Campa, Ramiro Flores-Ramírez, Sabrina Rojo-Garza, Edgar Francisco Carrizales-Sepúlveda, Diego Regalado-Ceballos, Raúl Reyes-Araiza, Neri Álvarez-Villalobos, Rene Rodríguez-Gutiérrez, José Ramón Azpiri-López   +8 more
doaj   +1 more source

Structural Changes of the Pancreas in Female Albino Rats Treated with the Atorvastatin and the Alleviating Effect of Propolis : Histological and Biochemical Study [PDF]

The Egyptian Journal of Histology
Introduction: Atorvastatin is "HMG-COA" reductase inhibitors" that is widely used for management of hyperlipidemia particularly in patients with risk of cardio and cerebrovascular stroke.
Eman sheet, zahraa taboo, waleed kasim
doaj   +1 more source

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, EarlyView.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

Solid dispersions of atorvastatin with Kolliphor RH40: enhanced supersaturation and improvement in a hyperlipidemic rat model

, 2023
Atorvastatin is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy. The aim of this study was to develop solid dispersions and micellar systems to obtain fastdissolving atorvastatin ...
Guarnizo Herrero, Victor, Peña Fernández, M. Ángeles, Torrado-Santiago, Santiago, Torrado Salmerón, Carlos Félix, Torre Iglesias, Paloma Marina De La, de la Torre-Iglesias, Paloma Marina, Torrado Durán, Guillermo, Peña, M. Ángeles, Guarnizo-Herrero, Víctor, Torrado Durán, Santiago, Torrado-Salmerón, Carlos, Torrado, Guillermo   +11 more
core   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, EarlyView.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

Journal of Lipid Research, 1998
The effects of atorvastatin on the expression of the hepatic HMG-CoA reductase and LDL receptor genes were investigated in rats. Like the other statins, atorvastatin increased the rate of degradation and presumably cycling of the hepatic LDL receptor. In
Gene C. Ness, Christopher M. Chambers, Dayami Lopez   +2 more
doaj   +1 more source